First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Autor: Bang YJ; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Giaccone G; Department of Medical Oncology, National Cancer Institute, Bethesda, MD, USA., Im SA; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Oh DY; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Bauer TM; Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA., Nordstrom JL; MacroGenics, Inc, Rockville, Maryland 20850, USA., Li H; MacroGenics, Inc, Rockville, Maryland 20850, USA., Chichili GR; MacroGenics, Inc, Rockville, Maryland 20850, USA., Moore PA; MacroGenics, Inc, Rockville, Maryland 20850, USA., Hong S; MacroGenics, Inc, Rockville, Maryland 20850, USA., Stewart SJ; Departamento de Física, Facultad de Ciencias Exactas, UNLP, IFLP-CONICET C.C.No. 67, 1900 La Plata, Argentina., Baughman JE; MacroGenics, Inc, South San Francisco, USA., Lechleider RJ; MacroGenics, Inc, Rockville, Maryland 20850, USA., Burris HA; Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Apr 01; Vol. 28 (4), pp. 855-861.